Wenn ich sehe, Aurora mit guter Meldung nicht einmal 1% Plus, Cronos ohne Meldung 3,5% Plus.
Aber ich denke mir, wenn ich jetzt von Aurora in Cronos wechsle, wird Aurora genau dann anspringen. Von der Performance her, ist Aurora von den Top5-Cannabis-Herstellern derjenige, der mit Abstand die schlechteste Performance aufweist. Vielleicht sollte sich Aurora um einen Investor umsehen - egal um welchen Preis, damit der Kurs anspringt.
Quote: (Albany, NY) The Senate today passed legislation that will address the racial disparities that are present in New York?s antiquated marijuana drug laws. New York?s existing marijuana laws disproportionately affect the African American and Latinx communities. This monumental legislation will decriminalize small amounts of marijuana and establish procedures for record expungements for both past and future convictions.
: Auszug von 5 Punkten von Aurora zum mit verfolgen!
Für große Marktteilnehmer denke ich ist der Eintritt in den US-Markt sehr wichtig und ich bin mir sicher dass Schritt für Schritt sich vorab positioniert wird: Der frühe Vogel fängt den Wurm !
One of the bigger questions on the minds of Wall Street and investors is when Aurora Cannabis will detail its entrance into the U.S. market. We've already seen close to half of Aurora's major competitors enter the U.S. hemp industry, thereby laying the processing and distribution infrastructure that would be needed if and when the U.S. federal government changes its tune on marijuana at the federal level. But as of now, Aurora hasn't outlined its plans for the U.S. market.
Back in mid-January, Aurora's chief corporate officer, Cam Battley, told Business Insider in an interview that "We'll be unveiling our hemp-derived CBD [cannabidiol] strategy to enter the U.S. market over the next few months." However, that time frame has come and gone with little mention of what Aurora's next steps are. As a company that prides itself on geographic expansion, it's almost a certainty that we'll hear about Aurora's U.S. CBD-market plans in the second half of 2019.
Aurora paid C$290 million for ICC Labs, and in my view it was well worth it; although I believe the Latin American market will take more time to develop than some of its European counterparts, even though the continent is more liberal in its outlook concerning cannabis than other regions of the world.
Part of that comes from the need to build up various aspects of infrastructure associated with the industry, as well as boost the amount of production capacity to meet demand in the market, along with competing in other markets.
In 2018 the Latin American market was valued at $125 million, and is projected to grow to $12.7 billion by 2028. I think it could be far larger than that.
Medical cannabis has been considered to be the largest segment of that market, but the rapid increase in production capacity in Columbia will probably change the product mix going forward, as it boosts low-cost recreational pot exports over time.